JBT Marel reported strong full-year 2025 results, demonstrating effective integration and execution post-combination, with a positive outlook for 2026 driven by demand recovery and synergy savings. The company successfully de-leveraged its balance sheet and achieved record quarterly orders and revenue.
Achieved record quarterly orders and revenue, both exceeding $1.0 billion.
positiveFull year 2025 revenue totaled $3.8 billion, with 50% generated from recurring revenue.
positiveRealized year-over-year synergy savings of approximately $43 million, with an annualized run rate of $85 million exiting 2025.
positiveDe-leveraged balance sheet by approximately 1.1x since the close of the transaction, with net debt to trailing twelve months adjusted EBITDA at 2.9x.
positiveFull year 2026 guidance reflects continued year-over-year growth in revenue (5-7%), margins, and earnings.
positiveFull year 2025 loss from continuing operations of $50 million, representing a margin of (1.3) percent, included significant charges: $179 million in acquisition related amortization and depreciation, $147 million in non-cash pension plan settlement costs, $115 million in M&A related costs, and $31 million in restructuring costs.
attentionGross profit margin decreased to 35.1% in FY2025 from 36.5% in FY2024, and operating income margin compressed to 5.0% from 6.9%.
attentionInventories increased to $643.7 million in FY2025 from $233.1 million in FY2024.
attentionFull year 2025 revenue included approximately $77 million in year-over-year foreign exchange translation benefit, and guidance for 2026 includes approximately 1 percent foreign exchange translation benefit.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Protein Solutions | N/A | — | — | — |
Prepared Food and Beverage Solutions | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Delivered strong full year financial results even in the face of a challenging tariff environment.
Demonstrated that we are truly better together, with excellent performance in 2025 and a positive outlook for 2026.
Benefited from demand recovery in the protein end markets, especially within poultry.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.